Tandem obtains approval for t:slim X2 insulin pump to use with Lyumjev

Tandem Diabetes Care has received European Union (EU) approval for its t:slim X2 insulin pump, featuring Control-IQ automated insulin delivery technology, to be used with Eli Lilly's ultra-rapid-acting insulin, Lyumjev (insulin lispro-aabc injection). This clearance follows the EU's general authorization of Lyumjev for insulin pump use in 2020, which required individual compatibility testing.

Tandem and Eli Lilly conducted clinical trials to demonstrate the benefits of using Lyumjev with Control-IQ technology. Their collaboration aims to expand compatibility for the t:slim X2 pump to other regions and the Tandem Mobi pump. A recent study showed high satisfaction and improved quality of life for users of Lyumjev with Control-IQ technology.

Ultra-rapid-acting insulin is popular for its quick response time. The t:slim X2 pump is also approved for several U-100 insulins globally. In February 2024, Tandem announced the US commercial launch of its Tandem Mobi insulin delivery system.